MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Clinical schizophrenia & related psychoses · 2015

Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.

Kelly Deanna L, Ben-Yoav Hadar, Payne Gregory F, Winkler Thomas E, Chocron Sheryl E, Kim Eunkyoung, Kitchen Christopher, Stock Veronika, Vyas Gopal, Love Raymond C, Wehring Heidi J, Sullivan Kelli M, Feldman Stephanie, Liu Fang, McMahon Robert P, Ghodssi Reza

СтатьяПеревод в очереди

Аннотация

BACKGROUND

While clozapine (CLZ) is the most effective antipsychotic drug for schizophrenia treatment, it remains underused. In order to understand the barriers of frequent blood draws for white blood cell counts (WBCs) and clozapine levels, we developed a psychiatrist survey and began an integrative approach of designing a point-of-care device that could eventually have real-time monitoring with immediate results.

METHODS

We ascertained barriers related to CLZ management and the acceptance of possible solutions by sending an anonymous survey to physicians in psychiatric practice (n=860). In parallel, we tested CLZ sensing using a prototype point-of-care monitoring device.

RESULTS

255 responses were included in the survey results. The two barriers receiving mean scores with the highest agreement as being a significant barrier were patient nonadherence to blood work and blood work's burden on the patient (out of 28). Among nine solutions, the ability to obtain lab results in the physician's office or pharmacy was top ranked (mean±sd Likert scale [4.0±1.0]). Physicians responded that a point-of-care device to measure blood levels and WBCs would improve care and increase CLZ use. Residents ranked point-of-care devices higher than older physicians (4.07±0.87 vs. 3.47±1.08, p<0.0001). Also, the prototype device was able to detect CLZ reliably in 1.6, 8.2, and 16.3 μg/mL buffered solutions.

DISCUSSION: Survey results demonstrate physicians' desire for point-of-care monitoring technology, particularly among younger prescribers. Prototype sensor results identify that CLZ can be detected and integrated for future device development. Future development will also include integration of WBCs for a complete detection device.

Для цитирования: Kelly Deanna L, Ben-Yoav Hadar, Payne Gregory F, Winkler Thomas E, Chocron Sheryl E, Kim Eunkyoung, Kitchen Christopher, Stock Veronika, Vyas Gopal, Love Raymond C, Wehring Heidi J, Sullivan Kelli M, Feldman Stephanie, Liu Fang, McMahon Robert P, Ghodssi Reza. Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.. Clinical schizophrenia & related psychoses. 2015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.